PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32477943-0	2020	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro.	sitravatinib	0-12	TXK tyrosine kinase	Homo sapiens	16-31	
32477943-1	2020	Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation.	sitravatinib	0-12	TXK tyrosine kinase	Homo sapiens	65-80	
32477943-1	2020	Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation.	sitravatinib	26-33	TXK tyrosine kinase	Homo sapiens	65-80	
32477943-1	2020	Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation.	sitravatinib	37-43	TXK tyrosine kinase	Homo sapiens	65-80